RXRX
Recursion Pharmaceuticals Inc
NASDAQ: RXRX · HEALTHCARE · BIOTECHNOLOGY
$3.30
-3.23% today
Updated 2026-04-29
Market cap
$1.80B
P/E ratio
—
P/S ratio
24.12x
EPS (TTM)
$-1.44
Dividend yield
—
52W range
$3 – $7
Volume
14.3M
Recursion Pharmaceuticals Inc (RXRX) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | $101.43M | $298.58M | $610.35M | $701.29M | $653.70M | $1.45B |
| Cash & equivalents | — | — | — | — | — | — |
| Current assets | $76.40M | $266.44M | $534.72M | $569.81M | $438.14M | $714.27M |
| Total liabilities | $225.70M | $504.87M | $67.41M | $215.48M | $190.26M | $413.82M |
| Current liabilities | $6.68M | $23.10M | $46.66M | $100.27M | $93.17M | $187.47M |
| Long-term debt | $12.42M | $11.41M | $633000.00 | $536000.00 | $1.10M | $19.02M |
| Shareholder equity | — | — | — | — | — | — |
| Retained earnings | $-126.59M | $-213.60M | $-400.08M | $-639.56M | $-967.62M | $-1.43B |
| Accounts receivable | $151000.00 | $156000.00 | $9.09M | $2.75M | $3.09M | $49.17M |
| Inventory | $5.29M | $5.04M | $1.55M | $1.28M | $-3.09M | — |
| Goodwill | — | $801000.00 | $801000.00 | $801000.00 | $52.06M | $148.87M |